What is HC Wainwright’s Estimate for AVBP FY2027 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Stock analysts at HC Wainwright issued their FY2027 earnings per share estimates for ArriVent BioPharma in a research note issued to investors on Monday, August 17th. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($4.24) for the year. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($3.96) per share.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.06).

AVBP has been the topic of a number of other research reports. Truist Financial lifted their price target on shares of ArriVent BioPharma from $43.00 to $45.00 and gave the company a “buy” rating in a report on Friday, May 29th. Citigroup reduced their target price on ArriVent BioPharma from $43.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday. BTIG Research reissued a “buy” rating and set a $42.00 price target on shares of ArriVent BioPharma in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Friday, July 17th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $45.00 price objective on shares of ArriVent BioPharma in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.86.

ArriVent BioPharma Stock Performance

AVBP opened at $29.01 on Tuesday. ArriVent BioPharma has a 1 year low of $17.00 and a 1 year high of $35.83. The company’s 50 day simple moving average is $31.76 and its 200 day simple moving average is $27.90. The stock has a market capitalization of $1.35 billion, a PE ratio of -8.01 and a beta of 1.36.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd acquired a new stake in ArriVent BioPharma during the 1st quarter valued at $266,000. Woodline Partners LP raised its holdings in ArriVent BioPharma by 0.4% in the first quarter. Woodline Partners LP now owns 146,373 shares of the company’s stock valued at $2,706,000 after acquiring an additional 576 shares in the last quarter. Jane Street Group LLC bought a new position in shares of ArriVent BioPharma during the first quarter worth about $189,000. Legal & General Group Plc lifted its holdings in ArriVent BioPharma by 8.8% during the 2nd quarter. Legal & General Group Plc now owns 14,790 shares of the company’s stock worth $322,000 after buying an additional 1,197 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in ArriVent BioPharma in the second quarter worth $206,000. 9.48% of the stock is owned by institutional investors and hedge funds.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.